A PYMNTS Company

US: Latest pharma merger earns antitrust clearance

 |  January 16, 2014

Valeant Pharmaceuticals International announced Wednesday its proposed buyout of Solta medical has earned regulatory clearance due to the expiration of the HSR waiting period, according to a press release.

The merger was first announced last month as Valeant revealed a purchase price of $250 million. The transaction included a share price of $2.92, the release said.

Full Content: RTT News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.